Ocugen, Inc. Common Stock (OCGN) Stock Price
OCGNStock
$0.78−51.53%52W
Market Cap$264.61M
P/E—
PEG Ratio—
Div yield—
Beta1.93
OCGN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-66.56%
Price vs S&P 500 (4W)-22.92%
VGM Score28.77
OCGN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.05 | -$0.06 | -16.92%(-$0.01) | |
| Q1 2026 | -$0.05 | -$0.06 | -15.38%(-$0.01) | |
| Q4 2025 | -$0.06 | -$0.06 | -4.35%(-$0.00) | |
| Q3 2025 | -$0.06 | -$0.07 | -21.74%(-$0.01) | |
| Q2 2025 | -$0.06 | -$0.05 | +11.77%(+$0.01) |
OCGN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.15
4.15
4.17
4.17
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
OCGNOcugen, Inc. Common Stock | F | C | D | 55.4x | 0.4% | — | — | $0.78 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Ocugen, Inc. Common Stock
Ocugen Inc develops gene therapies, cell therapies, and vaccines targeting unmet medical needs across multiple therapeutic areas. The company's primary focus is on retinal diseases, including inherited conditions such as retinitis pigmentosa and Leber congenital amaurosis, as well as age-related diseases including dry age-related macular degeneration and geographic atrophy. Its pipeline includes modifier gene therapy, novel biologics, regenerative medicine cell therapies, and inhaled mucosal vaccine platforms.